Lyra Therapeutics (LYRA)

• Market cap: $6.44M
• 1 day: -9.25%
• 5 days: -13.57%
• 1 month: -6.44%
• 3 months: -42.29%
• 6 months: -69.37%
• Year to date: -66.39%
• 1 year: -64.06%
• 5 years: -99.25%
• 10 years: -99.61%
• Sector: Healthcare
• Industry: Biotechnology

About: Lyra Therapeutics Inc is a clinical-stage therapeutics company focused on the development and commercialization of novel integrated drug and delivery solutions for the localized treatment of patients. The Company's operations and manages its business as a single operating segment which is the business of developing targeted medicines to address ears, nose, and throat, or ENT diseases. Its initial product candidates, LYR-210 and LYR-220, are bioabsorbable polymeric matrices designed to be administered in a brief, non-invasive, in-office procedure and intended to deliver continuous drug therapy to the sinonasal passages for the treatment of chronic rhinosinusitis, or CRS.

Employees: 87